Glaukos Corporation
GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's producā¦ read more
Healthcare
Medical Devices
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$89.86
Price-1.34%
-$1.22
1Y
Price
Market Cap
$5.153b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-20.3%
EBITDA Margin-47.7%
Net Profit Margin-40.7%
Free Cash Flow MarginRevenue
$432.953m
+3.7%
1y CAGR+3.7%
3y CAGR+10.5%
5y CAGREarnings
-$92.792m
-4.6%
1y CAGR-46.8%
3y CAGR-20.4%
5y CAGREPS
-$1.65
-3.6%
1y CAGR-44.0%
3y CAGR-17.9%
5y CAGRBook Value
$765.112m
$986.958m
Assets$221.846m
Liabilities$105.023m
DebtDebt to Assets
10.6%
-4.3x
Debt to EBITDAFree Cash Flow
-$53.239m
+3.6%
1y CAGR-64.7%
3y CAGR-42.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company